Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
Exdensur is the first and only ultra-long-acting biologic in the EU to treat respiratory diseasesGlaxoSmithKline plc (GSK)">Weiter zum vollständigen Artikel bei GlaxoSmithKline plc (GSK)
Quelle: EN, GlaxoSmithKline